Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.
  • TickerA1W7Q9
  • ISINBE0974260896
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryBelgium

Analysts

Emmanuel Matot ...
  • Florent Laroche-Joubert
  • Jerôme Bodin
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sylvain Goyon

ODDO BHF Small & MIDCAP MORNING NEWS - 07/08/2019

...

Emmanuel Matot ...
  • Florent Laroche-Joubert
  • Jerôme Bodin
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sylvain Goyon

ODDO BHF Small & MIDCAP MORNING NEWS - 08/07/2019

...

Bart Cuypers ...
  • Cedric Duinslaeger
  • Guy Sips
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs

Morning Note: BAMNB NA, CYAD BB, EXM BB, KIN BB, OBEL BB, PROX BB, ROU BB, TNET BB

BAM Group: Profit warning Celyad: CRC update sheds light on strategy going forward EXMAR: Financial update Kinepolis: € 225m bond placement Orange Belgium: New tariffs catalyst for BB-based competition Proximus: New tariffs impetus for increased competition Roularta: Tempers Storesquare ambitions Telenet: In the firing line

Gary Waanders

CELYAD: ESMO GI: encouraging SHRINK & ALLOSHRINK data | BUY | EUR49

CELYAD - BUY | EUR49 ESMO GI: encouraging SHRINK & ALLOSHRINK data SHRINK trial data ALLOSHRINK trial interim data Full ALLOSHRINK data by year-end 2019

Martial Descoutures ...
  • Pierre Corby

Celyad : A positive ESMO on gastrointestinal cancer for Celyad

>Positive results in CRCm - The group published on Friday morning the intermediate results of the phase I trial in refractory metastatic colorectal cancer at the European Society of Medical Oncology (ESMO) congress on gastrointestinal cancer in Barcelona. As a reminder, two phase I studies in the autologous form are currently underway in CRCm (without integrating the THINK basket trial including patients with haematological and solid cancers): 1) THINK CyFlu wher...

Bart Cuypers ...
  • Cedric Duinslaeger
  • Guy Sips
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs

Morning Note: BAMNB NA, CYAD BB, EXM BB, KIN BB, OBEL BB, PROX BB, ROU BB, TNET BB

BAM Group: Profit warning Celyad: CRC update sheds light on strategy going forward EXMAR: Financial update Kinepolis: € 225m bond placement Orange Belgium: New tariffs catalyst for BB-based competition Proximus: New tariffs impetus for increased competition Roularta: Tempers Storesquare ambitions Telenet: In the firing line

Gary Waanders

CELYAD: ESMO GI: encouraging SHRINK & ALLOSHRINK data | BUY | EUR49

CELYAD - BUY | EUR49 ESMO GI: encouraging SHRINK & ALLOSHRINK data SHRINK trial data ALLOSHRINK trial interim data Full ALLOSHRINK data by year-end 2019

Martial Descoutures ...
  • Pierre Corby

Celyad : A positive ESMO on gastrointestinal cancer for Celyad

>Positive results in CRCm - The group published on Friday morning the intermediate results of the phase I trial in refractory metastatic colorectal cancer at the European Society of Medical Oncology (ESMO) congress on gastrointestinal cancer in Barcelona. As a reminder, two phase I studies in the autologous form are currently underway in CRCm (without integrating the THINK basket trial including patients with haematological and solid cancers): 1) THINK CyFlu wher...

Martial Descoutures ...
  • Pierre Corby

Celyad : Un ESMO GI positif pour Celyad

>Des résultats positifs dans le CRCm - La société publiait vendredi matin ses résultats intermédiaires de phase I dans le cancer colorectal métastatiques (CRCm) au congrès de l’ESMO GI. Pour rappel, deux études de phase I dans la forme autologue sont actuellement en cours dans le CRCm (sans intégrer l’essai basket THINK incluant des patients ayant des cancers hématologiques et solides) : 1) THINK CyFlu où les patients inclus reçoivent en amont un pré conditionnem...

Gary Waanders

CELYAD: AML / MDS program strategic update | BUY | EUR49 (+313%)

CELYAD - BUY | EUR49 (+313%) AML / MDS program strategic update OptimAb manufacturing process – enriching more potent cells New and amended-existing INDs gain FDA acceptance Pipeline newsflow in next 12 months

A director sold 9,850 shares at 50.830EUR and

A director at Celyad sold 9,850 shares at 50.830EUR and the significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Emmanuel Matot ...
  • Florent Laroche-Joubert
  • Jerôme Bodin
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sylvain Goyon

ODDO BHF Small & MIDCAP MORNING NEWS - 07/08/2019

...

Emmanuel Matot ...
  • Florent Laroche-Joubert
  • Jerôme Bodin
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sylvain Goyon

ODDO BHF Small & MIDCAP MORNING NEWS - 08/07/2019

...

Ahmed Ben Salem ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Florent Laroche-Joubert
  • Jean-François Granjon
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Yassine Batini

ODDO BHF Small & MIDCAP MORNING NEWS - 07/02/2019

...

Jean-François Granjon ...
  • Jeremy Garnier
  • Martial Descoutures
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 06/17/2019

...

Jean-François Granjon ...
  • Jeremy Garnier
  • Martial Descoutures
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 17/06/2019

...

An unfavourable environment weighs on CELYAD, which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of CELYAD (BE), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date April 16, 2019, the closing price was EUR 19.02 and its target price was estimated at EUR 13.90.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch